Masterflex SE (ISIN: DE0005492938) announced preliminary results for the 2025 financial year, reporting record earnings and confirming its earlier forecasts. The company achieved consolidated revenue of EUR 102.6 million, a 4.6% increase from the prior year's EUR 98.1 million, within the projected range of EUR 100 million to EUR 105 million. Operating EBITDA rose 7.4% to EUR 19.5 million, and operating EBIT increased 9.8% to just under EUR 14.0 million, both setting new records. EBIT reached EUR 13.7 million, up 9.2% from EUR 12.5 million in 2024, falling within the forecast of EUR 12 million to EUR 15 million.
The positive results were driven by strong demand in the medical technology segment, which saw its share of consolidated revenue rise from 18% in 2024 to 21% in 2025. The US subgroup performed particularly well, while demand in the industrial sectors grouped under "Tech" and the trading business declined only moderately amid economic headwinds, especially in Germany. The order backlog remained stable at EUR 19.8 million, matching the previous year's level.
Despite currency losses and start-up costs for a new site in Morocco, the operating EBIT margin improved to 13.6% from 13.0% in the prior year. The company also strengthened its financial position, with the equity ratio increasing to 73.3% from 67.7% and net debt falling sharply to EUR 2.7 million from EUR 9.0 million. The debt ratio (net debt/EBITDA) improved to 0.1 from 0.5.
Dr. Andreas Bastin, CEO of Masterflex SE, commented: "Despite a continuing challenging economic environment, we met our forecasts in the 2025 financial year, achieved solid revenue growth and slightly increased our profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing. Building on this solid foundation, we are in a good position to continue our usual growth course in the coming years."
The preliminary figures are subject to confirmation by the auditors and approval by the Supervisory Board. The full 2025 consolidated financial statements and the 2026 forecast are scheduled for publication on 31 March 2026. More information is available in the original release.
